LyGenesis and Imagine Pharma to jointly develop cell therapies for Patients with Type 1 diabetes
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Subscribe To Our Newsletter & Stay Updated